trending Market Intelligence /marketintelligence/en/news-insights/trending/sebmZAIWUSGAchHY5f1Onw2 content esgSubNav
In This List

AMAG closes licensing agreement for Endoceutics' dyspareunia drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


AMAG closes licensing agreement for Endoceutics' dyspareunia drug

AMAG Pharmaceuticals Inc. closed a licensing agreement with Endoceutics Inc. for exclusive U.S. commercial rights to Intrarosa, a drug for the treatment of moderate-to-severe dyspareunia, a common symptom of vulvar and vaginal atrophy, due to menopause.

Intrarosa was approved in November 2016 and AMAG expects to launch Intrarosa in the U.S. in mid-2017.

Endoceutics and AMAG have also agreed to co-develop the product as a potential treatment for female sexual dysfunction in post-menopausal women.